KAREN A DAWES Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for KAREN A DAWES.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of KAREN A DAWES. KAREN A DAWES is Director in PDL BIOPHARMA, INC. ($PDLI) and Director in REPLIGEN CORP ($RGEN) and Director in DEPOMED INC ($DMI) and Director in Vaccitech plc ($VACC).
Latest Insider Trading Transactions of KAREN A DAWES
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, DMI, PDLI, RGEN, VACC
Page: 1
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
May 13 2021 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Option Exercise | M | 3.22 | 15,000 | 48,300 | 0 | |
May 13 2021 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Sell | S | 176.85 | 285 | 50,402 | 115,449 | 115.7 K to 115.4 K (-0.25 %) |
May 13 2021 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Buy | M | 3.22 | 15,000 | 48,300 | 115,734 | 100.7 K to 115.7 K (+14.89 %) |
May 06 2021 | VACC | Vaccitech plc | DAWES KAREN A | Director | Buy | P | 17.00 | 1,700 | 28,900 | 1,700 | 0 to 1.7 K |
May 04 2021 | VACC | Vaccitech plc | DAWES KAREN A | Director | Option Exercise | A | 17.00 | 34,328 | 583,576 | 34,328 | |
Jun 22 2020 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Sell | S | 116.56 | 2,568 | 299,326 | 100,734 | 103.3 K to 100.7 K (-2.49 %) |
Jun 22 2020 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Sell | S | 115.76 | 8,217 | 951,200 | 103,302 | 111.5 K to 103.3 K (-7.37 %) |
Jun 22 2020 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Sell | S | 114.49 | 5,243 | 600,271 | 111,519 | 116.8 K to 111.5 K (-4.49 %) |
Jun 22 2020 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Sell | S | 113.58 | 2,677 | 304,054 | 116,762 | 119.4 K to 116.8 K (-2.24 %) |
May 21 2020 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Sell | S | 140.29 | 182 | 25,533 | 119,439 | 119.6 K to 119.4 K (-0.15 %) |
May 21 2020 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Sell | S | 139.40 | 282 | 39,311 | 119,621 | 119.9 K to 119.6 K (-0.24 %) |
May 21 2020 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Sell | S | 136.98 | 43 | 5,890 | 119,903 | 119.9 K to 119.9 K (-0.04 %) |
May 21 2020 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Sell | S | 135.91 | 10 | 1,359 | 119,946 | 120 K to 119.9 K (-0.01 %) |
May 21 2020 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Sell | S | 140.29 | 182 | 25,533 | 119,439 | 119.6 K to 119.4 K (-0.15 %) |
May 21 2020 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Sell | S | 139.40 | 282 | 39,311 | 119,621 | 119.9 K to 119.6 K (-0.24 %) |
May 21 2020 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Sell | S | 136.98 | 43 | 5,890 | 119,903 | 119.9 K to 119.9 K (-0.04 %) |
May 21 2020 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Sell | S | 135.91 | 10 | 1,359 | 119,946 | 120 K to 119.9 K (-0.01 %) |
May 19 2020 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Option Exercise | A | 128.18 | 1,761 | 225,725 | 1,761 | |
May 19 2020 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Sell | S | 142.45 | 80 | 11,396 | 119,956 | 120 K to 120 K (-0.07 %) |
May 19 2020 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Sell | S | 141.45 | 77 | 10,892 | 120,036 | 120.1 K to 120 K (-0.06 %) |
May 19 2020 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Sell | S | 140.62 | 180 | 25,312 | 120,113 | 120.3 K to 120.1 K (-0.15 %) |
May 19 2020 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Sell | S | 139.32 | 122 | 16,997 | 120,293 | 120.4 K to 120.3 K (-0.10 %) |
May 19 2020 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Sell | S | 138.60 | 269 | 37,283 | 120,415 | 120.7 K to 120.4 K (-0.22 %) |
May 19 2020 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Sell | S | 136.92 | 160 | 21,907 | 120,684 | 120.8 K to 120.7 K (-0.13 %) |
May 19 2020 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Sell | S | 135.76 | 712 | 96,661 | 120,844 | 121.6 K to 120.8 K (-0.59 %) |
May 19 2020 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Grant | A | 0.00 | 722 | 0 | 121,556 | 120.8 K to 121.6 K (+0.60 %) |
May 11 2020 | DMI | Assertio Therapeut ... | DAWES KAREN A | Director | Sell | S | 0.79 | 15,834 | 12,531 | 84,589 | 100.4 K to 84.6 K (-15.77 %) |
Apr 22 2020 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Option Exercise | M | 3.30 | 11,800 | 38,940 | 0 | |
Apr 22 2020 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Option Exercise | M | 3.30 | 8,200 | 27,060 | 11,800 | |
Apr 22 2020 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Buy | M | 3.30 | 11,800 | 38,940 | 120,834 | 109 K to 120.8 K (+10.82 %) |
Apr 22 2020 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Sell | S | 104.42 | 8,998 | 939,571 | 109,034 | 118 K to 109 K (-7.62 %) |
Apr 22 2020 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Sell | S | 104.98 | 3,202 | 336,146 | 118,032 | 121.2 K to 118 K (-2.64 %) |
Apr 22 2020 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Buy | M | 3.30 | 8,200 | 27,060 | 121,234 | 113 K to 121.2 K (+7.25 %) |
Feb 24 2020 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Sell | S | 97.52 | 1,849 | 180,314 | 113,034 | 114.9 K to 113 K (-1.61 %) |
Feb 24 2020 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Sell | S | 99.12 | 906 | 89,803 | 114,883 | 115.8 K to 114.9 K (-0.78 %) |
Feb 24 2020 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Sell | S | 99.85 | 945 | 94,358 | 115,789 | 116.7 K to 115.8 K (-0.81 %) |
Feb 24 2020 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Sell | S | 101.06 | 300 | 30,318 | 116,734 | 117 K to 116.7 K (-0.26 %) |
Jun 19 2019 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Option Exercise | M | 4.96 | 20,000 | 99,200 | 0 | |
Jun 19 2019 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Sell | S | 77.35 | 1,295 | 100,168 | 117,034 | 118.3 K to 117 K (-1.09 %) |
Jun 19 2019 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Buy | M | 4.96 | 20,000 | 99,200 | 118,329 | 98.3 K to 118.3 K (+20.34 %) |
Jun 14 2019 | DMI | Assertio Therapeut ... | DAWES KAREN A | Director | Sell | S | 3.18 | 12,500 | 39,794 | 100,423 | 112.9 K to 100.4 K (-11.07 %) |
May 17 2019 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Option Exercise | A | 67.71 | 2,953 | 199,948 | 2,953 | |
May 17 2019 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Grant | A | 0.00 | 1,292 | 0 | 98,329 | 97 K to 98.3 K (+1.33 %) |
May 09 2019 | DMI | Assertio Therapeut ... | DAWES KAREN A | Director | Option Exercise | M | 0.00 | 31,250 | 0 | 0 | |
May 09 2019 | DMI | Assertio Therapeut ... | DAWES KAREN A | Director | Buy | M | 0.00 | 31,250 | 0 | 112,923 | 81.7 K to 112.9 K (+38.26 %) |
May 09 2019 | DMI | Assertio Therapeut ... | DAWES KAREN A | Director | Grant | A | 0.00 | 39,584 | 0 | 81,673 | 42.1 K to 81.7 K (+94.05 %) |
Dec 04 2018 | DMI | Assertio Therapeut ... | DAWES KAREN A | Director | Option Exercise | M | 1.49 | 15,000 | 22,350 | 0 | |
Dec 04 2018 | DMI | Assertio Therapeut ... | DAWES KAREN A | Director | Sell | S | 4.84 | 8,421 | 40,725 | 42,089 | 50.5 K to 42.1 K (-16.67 %) |
Dec 04 2018 | DMI | Assertio Therapeut ... | DAWES KAREN A | Director | Buy | M | 1.49 | 15,000 | 22,350 | 50,510 | 35.5 K to 50.5 K (+42.24 %) |
May 17 2018 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Option Exercise | A | 42.07 | 4,626 | 194,616 | 4,626 | |
May 17 2018 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Grant | A | 0.00 | 2,080 | 0 | 97,037 | 95 K to 97 K (+2.19 %) |
May 15 2018 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Option Exercise | M | 5.08 | 20,000 | 101,600 | 0 | |
May 15 2018 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Sell | S | 41.80 | 20,000 | 835,936 | 94,957 | 115 K to 95 K (-17.40 %) |
May 15 2018 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Buy | M | 5.08 | 20,000 | 101,600 | 114,957 | 95 K to 115 K (+21.06 %) |
May 10 2018 | DMI | DEPOMED INC | DAWES KAREN A | Director | Option Exercise | A | 0.00 | 31,250 | 0 | 31,250 | |
Aug 16 2017 | DMI | DEPOMED INC | DAWES KAREN A | Director | Option Exercise | A | 0.00 | 19,512 | 0 | 19,512 | |
May 22 2017 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Option Exercise | A | 38.76 | 3,459 | 134,071 | 3,459 | |
May 22 2017 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Grant | A | 0.00 | 1,714 | 0 | 94,957 | 93.2 K to 95 K (+1.84 %) |
Mar 22 2017 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Option Exercise | M | 4.29 | 20,000 | 85,800 | 0 | |
Mar 22 2017 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Sell | S | 34.12 | 2,521 | 86,017 | 93,243 | 95.8 K to 93.2 K (-2.63 %) |
Mar 22 2017 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Buy | M | 4.29 | 20,000 | 85,800 | 95,764 | 75.8 K to 95.8 K (+26.40 %) |
Jul 15 2016 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Grant | A | 0.00 | 20,000 | 0 | 75,764 | 55.8 K to 75.8 K (+35.87 %) |
Jun 28 2016 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Option Exercise | M | 3.10 | 15,000 | 46,500 | 0 | |
Jun 28 2016 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Option Exercise | M | 3.10 | 15,000 | 46,500 | 0 | |
Jun 28 2016 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Payment of Exercise | F | 23.46 | 1,982 | 46,498 | 55,764 | 57.7 K to 55.8 K (-3.43 %) |
Jun 28 2016 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Payment of Exercise | F | 23.46 | 1,982 | 46,498 | 55,764 | 57.7 K to 55.8 K (-3.43 %) |
Jun 28 2016 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Buy | M | 3.10 | 15,000 | 46,500 | 57,746 | 42.7 K to 57.7 K (+35.09 %) |
Jun 28 2016 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Buy | M | 3.10 | 15,000 | 46,500 | 57,746 | 42.7 K to 57.7 K (+35.09 %) |
May 20 2016 | DMI | DEPOMED INC | DAWES KAREN A | Director | Option Exercise | A | 0.00 | 3,131 | 0 | 3,131 | |
May 20 2016 | DMI | DEPOMED INC | DAWES KAREN A | Director | Option Exercise | A | 19.16 | 7,669 | 146,938 | 7,669 | |
May 13 2016 | DMI | DEPOMED INC | DAWES KAREN A | Director | Payment of Exercise | F | 17.52 | 734 | 12,860 | 12,867 | 13.6 K to 12.9 K (-5.40 %) |
May 13 2016 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Option Exercise | A | 26.12 | 4,783 | 124,932 | 4,783 | |
May 13 2016 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Grant | A | 0.00 | 2,505 | 0 | 42,746 | 40.2 K to 42.7 K (+6.22 %) |
Dec 03 2015 | DMI | DEPOMED INC | DAWES KAREN A | Director | Payment of Exercise | F | 19.00 | 1,198 | 22,762 | 10,665 | 11.9 K to 10.7 K (-10.10 %) |
Nov 12 2015 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Grant | A | 26.70 | 1,000 | 26,700 | 40,241 | 39.2 K to 40.2 K (+2.55 %) |
May 26 2015 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Option Exercise | A | 41.19 | 2,929 | 120,646 | 2,929 | |
May 26 2015 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Grant | A | 0.00 | 1,498 | 0 | 39,241 | 37.7 K to 39.2 K (+3.97 %) |
May 13 2015 | DMI | DEPOMED INC | DAWES KAREN A | Director | Option Exercise | A | 0.00 | 2,936 | 0 | 2,936 | |
May 13 2015 | DMI | DEPOMED INC | DAWES KAREN A | Director | Option Exercise | A | 20.43 | 7,857 | 160,519 | 7,857 | |
Oct 03 2005 | PDLI | PDL BIOPHARMA, INC ... | DAWES KAREN A | Director | Option Exercise | A | 27.87 | 3,000 | 83,610 | 3,000 | |
Jun 10 2005 | PDLI | PDL BIOPHARMA, INC ... | DAWES KAREN A | Director | Option Exercise | A | 18.28 | 1,000 | 18,280 | 1,000 | |
Jun 10 2005 | PDLI | PDL BIOPHARMA, INC ... | DAWES KAREN A | Director | Option Exercise | A | 18.28 | 3,000 | 54,840 | 3,000 | |
Jun 10 2005 | PDLI | PDL BIOPHARMA, INC ... | DAWES KAREN A | Director | Option Exercise | A | 18.28 | 3,000 | 54,840 | 3,000 | |
Jun 10 2005 | PDLI | PDL BIOPHARMA, INC ... | DAWES KAREN A | Director | Option Exercise | A | 18.28 | 15,000 | 274,200 | 15,000 | |
May 26 2005 | PDLI | PDL BIOPHARMA, INC ... | DAWES KAREN A | Director | Option Exercise | M | 13.55 | 2,000 | 27,100 | 250 | |
May 26 2005 | PDLI | PDL BIOPHARMA, INC ... | DAWES KAREN A | Director | Buy | M | 13.55 | 2,000 | 27,100 | 2,000 | 0 to 2 K |
Feb 22 2005 | PDLI | PDL BIOPHARMA, INC ... | DAWES KAREN A | Director | Option Exercise | A | 17.44 | 3,000 | 52,320 | 3,000 | |
Jul 26 2004 | PDLI | PDL BIOPHARMA, INC ... | DAWES KAREN A | Director | Option Exercise | A | 15.30 | 3,000 | 45,900 | 3,000 | |
Jul 01 2004 | PDLI | PDL BIOPHARMA, INC ... | DAWES KAREN A | Director | Option Exercise | A | 19.13 | 12,000 | 229,560 | 12,000 | |
Jul 01 2004 | PDLI | PDL BIOPHARMA, INC ... | DAWES KAREN A | Director | Option Exercise | A | 19.13 | 3,000 | 57,390 | 3,000 | |
Nov 26 2003 | PDLI | PDL BIOPHARMA, INC ... | DAWES KAREN A | Director | Option Exercise | A | 13.55 | 2,250 | 30,488 | 2,250 |
Page: 1